Showing 76–100 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Kwak N, Kim JY, Kim HJ, Kwon BS, Lee JH, et al.
Background This study aimed to determine whether a shorter high-dose rifampicin regimen is non-inferior to the standard 6-month tuberculosis regimen. Methods This multicenter, randomized, open-label, non-inferiority trial enrolled participants with respiratory specimen positivity…
Nogdallah S, Mustafa MEAE, Khairy AM, Fatooh M, Abd-Elmaged HMA
Key clinical message It is important to consider foot and ankle tuberculosis (TB) as a potential cause of cystic lesion around the ankle, especially in patients with a history of TB. Early diagnosis and treatment with a rifampin-based regimen for a duration of 12 months can lead …
Laura Diab Casares, Juan Espinosa Pereiro, María Teresa Tórtola Fernández, Xavier Casas García, Joan Pau Millet, et al.
…ceptible (DS)-TB with equal or better efficacy than current regimens. A promising approach to achieve this is the combination of dose-optimised repurposed drugs. **METHODS AND ANALYSIS:** The RML-TB trial is a phase IIb, randomised, non-inferiority, controlled, open-label, multi…
Izudi J, Okello G, Bajunirwe F
Rationale In 2017, the treatment regimen for previously treated persons with tuberculosis (TB) changed to a shorter regimen that lasts six months and consists of Isoniazid, Rifampicin, Pyrazinamide, and Ethambutol. Few studies have examined treatment success rate (TSR) among prev…
Ruchita A Sakaria, Bina Modi, Anjana MS, Bharti Koria, Kamlesh Vithalani
… DR-TB cases remains limited, bedaquiline-based oral longer regimens have shown promising results in select studies. Objective: This study aimed to evaluate whether a patient’s prior TB status influences treatment outcomes under a bedaquiline-based regimen and to assess other pre…
Usharani Brammachary, Venkateswari Ramachandra, Suganthi Palavesam, Vidya Raj Cuppusamy Kapalamurthy, Aaina Muralidhar, et al.
…allenging infection to treat worldwide. The contemporary TB regimens consist of 6–9 months of daily doses of four drugs in the existing regimen that is extremely toxic to patients. The purpose of these longer treatments is to eliminate Mycobacterium tuberculosis, notorious for it…
Christian Noel Dide-Agossou
New shorter treatment regimens for both drug-susceptible and drug-resistant tuberculosis (TB) are urgently needed. The key roadblock in TB regimen development is lack of valid surrogate pharmacodynamic markers for TB relapse. A recently-proposed assay called the ribosomal RNA (rR…
Christian Noel Dide-Agossou
New shorter treatment regimens for both drug-susceptible and drug-resistant tuberculosis (TB) are urgently needed. The key roadblock in TB regimen development is lack of valid surrogate pharmacodynamic markers for TB relapse. A recently-proposed assay called the ribosomal RNA (rR…
Simran Sharma, Rohit Ajitsingh Macharekar, Tirumalai R. Raghunand
…roteins, becomes crucial to developing innovative treatment regimens to significantly improve patient outcomes. This review presents the state-of-art knowledge about transporters that help M. tb maintain nutrient uptake from the host and extrude toxic compounds, including antibio…
Kurbatova EV, Phillips PPJ, Dorman SE, Sizemore EE, Bryant KE, et al.
…an open-label trial comparing two 4-month rifapentine-based regimens with a standard 6-month regimen for the treatment of pulmonary tuberculosis (TB). Objectives: We describe the use of the PPTR process and evaluate whether the goals of minimizing bias in efficacy endpoint assess…
Dodd M, Carpenter J, Thompson JA, Williamson E, Fielding K, et al.
…ethods The REMoxTB trial evaluated two 4-month experimental regimens compared with a 6-month control regimen for newly diagnosed drug-susceptible TB. The primary endpoint was a composite unfavorable outcome of treatment failure or recurrence within 18 months post-randomization. W…
Tweed CD, Wills GH, Crook AM, Amukoye E, Balanag V, et al.
BACKGROUND: Treatment for TB is lengthy and toxic, and new regimens are needed. METHODS: Participants with pulmonary drug-susceptible TB (DS-TB) were randomised to receive: 200 mg pretomanid (Pa, PMD) daily, 400 mg moxifloxacin (M) and 1500 mg pyrazinamide (Z) for 6 months (6Pa 2…
Stadler JAM, Maartens G, Meintjes G, Wasserman S
Shorter (6-9 months), fully oral regimens containing new and repurposed drugs are now the first-choice option for the treatment of drug-resistant tuberculosis (DR-TB). Clofazimine, long used in the treatment of leprosy, is one such repurposed drug that has become a cornerstone of…
Mashele SA, Steel HC, Matjokotja MT, Rasehlo SSM, Anderson R, et al.
Objectives The chemotherapeutic regimens of patients with drug-susceptible (DS)- tuberculosis (TB) comprise four primary anti-TB drugs: rifampicin (RMP), isoniazid (INH), ethambutol (EMB) and pyrazinamide (PZA), administered for six-to-nine months. These drug regimens target the …
Haigh KA, Twabi HH, Boloko L, Namale PE, Lutje V, et al.
…were performed using random effects models where background regimens were the same. Risk ratio was used as the measure for treatment effect. Outcomes of interest related to efficacy and safety. Findings Of the 5441 total records identified by our searches, nineteen studies (6332 …
Alexandra V. Solovyeva, Grigory Volchenkov, O. Ponomarenko, Tatiana A. Kuznezova, Tatiana R. Somova, et al.
…alt infection progression and transmission. While newer TPT regimens for drug-sensitive strains are expanding, optimal treatment for contacts exposed to drug-resistant TB (DR-TB) remains unclear. In 2019-2020, Vladimir City, Russia, introduced moxifloxacin and bedaquiline-based T…
Lanni A, Iacobino A, Fattorini L, Giannoni F
…linical trials, in order to shorten the duration of current regimens against TB. In 2022, the World Health Organization, following the results of one of these trials, supported the use of a 4-month regimen for the treatment of drug-susceptible TB as a possible alternative to the …
Styliani Karanika, Tianyin Wang, Addis Yilma, Jennie Ruelas Castillo, James T. Gordy, et al.
…-resistant regimen, rendering it effective across treatment regimens, and also showed promising results in CD4+ knockout mice, perhaps due to enhanced Rel-specific CD8+ T-cell responses. Notably, our novel fusion vaccine was also immunogenic in nonhuman primates, the gold standar…
National Institute of Allergy and Infectious Diseases (NIAID)
…ts effectiveness. Current 6-month short course chemotherapy regimens are over 95% effective for the treatment of tuberculosis when fully administered. Six months is a long time, however, and patients frequently discontinue anti-TB treatment once their symptoms have improved. The …
Serena Koenig, MD, MPH, Sean Wasserman, MBChB, PhD
The PRESCIENT trial is a Phase IIc, open-label, randomized trial that will compare a 12-week regimen of bedaquiline (BDQ), clofazimine (CFZ), pyrazinamide (PZA), and delamanid (DLM) with standard treatment for drug-susceptible pulmonary tuberculosis. Eligible participants will be…
Wilber Sabiiti, Emmanuel Musisi, Bariki Mtafya, Peter M. Mbelele, Khalide Azam, et al.
…001) during treatment. Like MGIT, TB-MBLA demonstrated that regimens containing rifampicin-35mg/kg and rifampicin-20mg/kg-400mg-moxifloxacin cleared TB bacteria significantly faster than the standard-of-care regimen by month-2 of treatment, p=0.049 and p=0.008 respectively in DS-…
Yang Li, Lingyun Song, Zhen Feng, Xiaoqiang Zhang, Yan Miao, et al.
… randomly divided (1:1:1:1) to receive one of three 4-month regimens containing rifapentine 10, 15, or 20 mg/kg daily plus isoniazid, moxifloxacin, and pyrazinamide, or a standard 6-month regimen consisting of isoniazid, rifampicin, pyrazinamide, and ethambutol. In the stage 1, t…
Ang MLT, Chan SM, Cheng LT, Cheong HY, Chew KL, et al.
… of TB, ranging from diagnostics to new drugs and treatment regimens. The National TB Programme convened a multidisciplinary panel to update guidelines for the clinical management of drug-susceptible TB infection and disease in Singapore, contextualising current evidence for loca…
Dillon Prus, Robert Lenox
…idence. As global TB guidelines shift toward four-month MXF regimens, this report highlights a critical safety consideration for clinicians and the importance of routine neurological screening throughout the entire treatment course to detect early signs of toxicity and prevent th…
Christopher Cousins, MBChB PhD, Sean Wasserman, MBChB PhD, John Eikelboom, MBBS FRCPC
RIFAstrat is a Phase 3, double-blind, placebo-controlled, non-inferiority trial to compare the 6-month standard treatment for DS-TB with a 4-month optimised- rifampicin based regimen provided to individuals with limited disease severity. RIFAstrat is a Phase 3, double-blind, pla…